

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



Figure 1



whereto

R¹, R² and R³ are each independently of the others an aliphatic hydrocarbon radical having from 7 to 21 carbon atoms.


n is 0 or 1.

As is the amidically bonded residue of a (D)- or (L)-amino acid or of a (D)- or (L)-amino acid derivative from the group consisting of Gly, Ala, Ser, Thr, Asp, Asp(R⁵), Glu, Glu(R⁵), Gla, Gla(R⁵) and Gla(R⁵)₂, and

R^4 and R^5 are each independently of the other the amidically bonded radical of an unsubstituted or carboxy-substituted α -amino- C_2-C_7 alkanesulfonic acid.

O I P E
M A R 1 5 2024
P A T E N T & T R A D E M A R K O F F I C E 9 9 C

Figure 2



JBT3002, $C_{55}H_{102}N_4O_{14}S_3Na_2$ (1185.6)

dc-101415




Figure 3





Figure 4



MLV-JT3002

(A)

133

71

42

31


kDa

10' 20' 30' 4h 24h



45 kD
41 kD
39 kD

β -actin



IFN γ

+

+

-

+

+

+

+

+

LPS

-

15'

-

-

-

-

-

-

MLV-JT3002

- - - 5' 10' 20' 30' 120'

(B)

133

71

42

31

kDa



45 kD
41 kD
39 kD

β -actin




Figure 5








Figure 6




Figure 7

Fig. 7




Figure 8




Figure 9




Figure 10





Figure 11

O I P E
M A R 1 5 2004
95
TRADEMARK OFFICE
PARENTS & TRADEMARK OFFICE




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19

O I P E
MAR 15 2004
JG56
PATENT & TRADEMARK OFFICE

COPY

CONFIDENTIAL

PBS followed by CPT-PE



Oral MFP-PE followed by CPT





Figure 20



COPY CONFIDENTIAL

Figure 21



O I P E
MAR 15 2004
PATENT & TRADEMARK OFFICE 950

ILEUM


Control

CPT-11

JBT3002

JBT3002/CPT-11

H & E



BrdUrd

IL-15




Fig 22



IL-15 RT-PCR




Fig 23